Exelixis is stretching cabozantinib’s cash-flow runway to 2030 while racing zanzalintinib toward a first launch that could turn a one-franchise biotech into a multi-franchise oncology platform.
The contemporary pharmaceutical landscape for mid-cap oncology specialists is defined by the rigorous pursuit of franchise durability and the successful navigation of looming patent horizons. As of May 5, 2026, Exelixis Inc. (EXEL) stands at a critical juncture in its corporate trajectory, transitioning from a single-product success story centered on cabozantinib to a multi-franchise commercial force with a diversified pipeline of next-generation inhibitors and antibody-drug conjugates.[1, 2, 3] The release of the first-quarter 2026 financial results marks a pivotal milestone, reflecting the company’s ability to sustain high-margin growth while funding an ambitious pivot toward zanzalintinib and its earlier-stage clinical assets.[4, 5, 6] This analysis provides an exhaustive review of the organization’s fiscal health, clinical milestones, intellectual property defense strategies, and broader market positioning within the global solid tumor oncology segment.
The financial results reported on May 5, 2026, underscore a period of robust operational execution. Exelixis reported first-quarter earnings of $210.5 million, translating to a GAAP net income of $0.79 per share.[4] On an adjusted basis, accounting for stock-based compensation and non-recurring items, the company achieved an earnings per share (EPS) of $0.87, significantly outperforming the Zacks Consensus Estimate of $0.75.[4, 5] This 15.55% earnings surprise follows a consistent pattern of outperformance; in the preceding quarter, the company delivered a 22.08% surprise by reporting an EPS of $0.94 against an expectation of $0.77.[5, 7, 8]
While profitability remains a core strength, revenue dynamics for the first quarter of 2026 presented a more nuanced picture. Total revenue reached $610.8 million, representing a significant year-over-year increase from the $555.45 million reported in the first quarter of 2025.[5] However, this figure fell slightly short of the $612.57 million to $612.6 million anticipated by Wall Street analysts.[4, 5] This marginal revenue miss, estimated at approximately 0.29%, reflects the complexities of the highly competitive renal cell carcinoma (RCC) and neuroendocrine tumor (NET) markets, where the company’s market leadership must be defended against intensifying combination therapy benchmarks from larger pharmaceutical peers.[3, 5, 7]
The broader fiscal year 2025 served as a foundational period for the company’s current guidance. Preliminary and confirmed results for 2025 indicate that total revenues reached approximately $2.32 billion, a 7% increase over 2024, driven primarily by the cabozantinib franchise’s 17% growth in U.S. net product revenues.[9, 10, 11] The company maintained its ninth consecutive year of operating profitability, a feat that distinguishes it from many of its biotech peers.[11]
| Financial Metric | Q1 2026 (Actual) | FY 2025 (Actual/Prelim) | FY 2026 Guidance Range |
|---|---|---|---|
| Total Revenues | $610.81M | $2,320.1M | $2.525B - $2.625B |
| Net Product Revenues | ~$560M* | $2,122.8M | $2.325B - $2.425B |
| Research & Development | ~$225M* | $825.0M | $875M - $925M |
| SG&A Expenses | ~$145M* | $518.7M | $575M - $625M |
| GAAP Diluted EPS | $0.79 | $2.78 | $3.41 (Est.) |
| Non-GAAP Diluted EPS | $0.87 | $3.08 | N/A |
*Note: Q1 2026 component estimates extrapolated from aggregate earnings snapshots.[4, 5, 9, 10, 12, 13]
Management has maintained its previously issued 2026 financial guidance, projecting total revenues between $2.525 billion and $2.625 billion.[9, 14] This guidance assumes a 3.0% wholesale acquisition cost (WAC) increase for both CABOMETYX and COMETRIQ, effective January 1, 2026.[9, 14, 15] Crucially, these projections do not yet factor in potential commercial revenues from zanzalintinib, should it receive FDA approval for metastatic colorectal cancer (mCRC) by its December 3, 2026, PDUFA date.[9, 13, 16] The commitment to high levels of research and development (R&D) spending—projected at $875 million to $925 million for 2026—highlights the company’s focus on long-term pipeline maturation over short-term margin maximization.[9, 17]
The commercial foundation of Exelixis remains the cabozantinib franchise, which includes CABOMETYX and COMETRIQ. This flagship asset is a multi-kinase inhibitor targeting MET, VEGF, and the TAM kinases (TYRO3, AXL, MER), making it uniquely suited for overcoming resistance to single-pathway VEGF therapies.[1, 16, 18] In the U.S. market, the franchise generated $2.123 billion in net product revenues during 2025, with $546.6 million achieved in the fourth quarter alone.[9]
In the renal cell carcinoma segment, CABOMETYX continues to hold its position as the number one prescribed tyrosine kinase inhibitor (TKI) and the most utilized TKI in combination with immunotherapy (IO).[14, 19, 20] The molecule’s clinical utility across multiple lines of therapy—including as a monotherapy in the second line and in combination with nivolumab in the first line—provides a diversified revenue base that limits downside risk from emerging single-indication competitors.[3, 21]
The competitive landscape in RCC is increasingly defined by the debate between sequencing therapies and immediate triplet combinations. While rivals such as Merck, with the Lenvima and Keytruda combination, and Bristol Myers Squibb, with Opdivo and Yervoy, maintain significant 1L market share, Exelixis has focused on the clinical value of "TKI breaks" and sequencing approaches.[2] The company argues that the high toxicity of certain triplet regimens, which can lead to discontinuation rates as high as 40%, creates a durable market for well-tolerated sequencing options where CABOMETYX serves as the backbone.[2]
A significant driver of the company’s recent momentum is the label expansion into neuroendocrine tumors. Approved in March 2025 for advanced pancreatic and extra-pancreatic NET (pNET and epNET), CABOMETYX has seen rapid adoption as the leading oral therapy in the 2L+ NET market.[14, 17] This approval followed the results of the phase 3 CABINET study, which demonstrated a statistically significant improvement in progression-free survival (PFS) for both pNET (13.8 months vs. 3.3 months for placebo) and epNET (8.5 months vs. 4.2 months).[2]
The NET indication represents an estimated $1 billion market opportunity in the oral segment alone.[2] During 2025, the NET launch contributed over $100 million in U.S. net product revenue, a trajectory that management expect to accelerate in 2026 as the full buildout of the gastrointestinal (GI) sales team is completed.[19, 20] This strategic expansion of the sales force is not merely defensive; it is a proactive measure to establish the commercial infrastructure required for the impending launch of zanzalintinib in colorectal cancer.[10, 14, 22]
The global reach of cabozantinib is expanded through strategic alliances with Ipsen Pharma for territories outside the U.S. and Japan, and Takeda for the Japanese market.[1, 9] In 2025, global franchise revenues (including partner sales) reached $2.9 billion.[9] For Exelixis, this translates into high-margin royalty revenue, which totaled $52.8 million in the fourth quarter and $179.2 million for the full year 2025.[9] Although total collaboration revenues saw a year-over-year decrease in 2025 due to the timing of milestone payments, the underlying volume of global product sales remains robust, providing a stable source of non-dilutive capital to fund pipeline innovation.[9, 10]
The most critical element of the Exelixis growth thesis is the successful development and commercialization of zanzalintinib (XL092). Designed as a follow-on molecule to cabozantinib, zanzalintinib targets the same core kinases but features a significantly improved pharmacokinetic (PK) profile, including a shorter half-life of less than 24 hours compared to the four-day half-life of its predecessor.[2, 16]
The immediate catalyst for the company is the potential FDA approval of zanzalintinib in combination with atezolizumab (Tecentriq) for previously treated metastatic colorectal cancer. The FDA accepted the New Drug Application (NDA) for this indication in February 2026, setting a PDUFA date of December 3, 2026.[2, 18, 23] This filing is anchored by the STELLAR-303 study, which met its dual primary endpoint of overall survival (OS) in the intention-to-treat (ITT) population, demonstrating a 20% reduction in the risk of death compared to regorafenib.[2, 14, 16]
| Zanzalintinib Clinical Catalyst | Trial / Indication | Expected Timing | Strategic Importance |
|---|---|---|---|
| Final Analysis OS (NLM) | STELLAR-303 (mCRC) | Mid-2026 | Bolsters messaging for patients without liver metastases.[2, 14] |
| Topline Results | STELLAR-304 (nccRCC) | Mid-2026 | Expansion into a niche kidney cancer segment with high unmet need.[2, 14] |
| PDUFA Date | mCRC Combination | Dec 3, 2026 | Potential first commercial launch for the zanzalintinib franchise.[16, 22] |
| Trial Initiation | STELLAR-316 (Adj. CRC) | Mid-2026 | Moves zanzalintinib into earlier-line adjuvant settings.[14, 24] |
| Trial Initiation | STELLAR-201 (Meningioma) | Mid-2026 | Investigates expansion into rare neuro-oncology indications.[9, 14] |
The shorter half-life of zanzalintinib is a profound clinical differentiator. In modern oncology, where dose interruptions and symptom management are frequent hurdles, a drug that clears the system more rapidly allows for more manageable dose holds and quicker resolution of side effects.[2, 22] This makes zanzalintinib an ideal candidate for combination therapy, particularly with immunotherapies like atezolizumab or nivolumab, where managing overlapping toxicities is paramount to long-term patient compliance.[2, 22]
Management’s broader strategy for zanzalintinib involves a "second-wave" expansion across multiple high-value oncology indications. With seven pivotal studies ongoing or planned, the company believes zanzalintinib could unlock a peak annual sales opportunity of $5 billion.[2, 22] Key among these is the STELLAR-304 study in non-clear cell RCC (nccRCC), which accounts for 15% to 20% of the total RCC population and represents a significant white space in the market currently underserved by existing standards of care.[2]
Furthermore, the collaboration with Natera to utilize the Signatera minimal residual disease (MRD) assay in the STELLAR-316 adjuvant CRC trial illustrates a sophisticated approach to clinical trial design.[14, 24] By using circulating tumor DNA (ctDNA) to identify and monitor high-risk patients, Exelixis is moving toward a precision medicine model that could increase the probability of clinical success and demonstrate the drug’s utility in earlier stages of disease where the opportunity for curative intent is greater.[20, 24]
To achieve its goal of becoming a top-five solid tumor oncology company, Exelixis is aggressively diversifying its pipeline beyond its traditional expertise in small molecule kinase inhibitors. This includes a significant commitment to antibody-drug conjugates (ADCs) and bispecific antibodies, modalities that offer targeted delivery of cytotoxic agents or simultaneous modulation of multiple immune pathways.[2, 14]
The company is advancing several ADC candidates, notably XB010 and XB371. XB010 is a next-generation ADC targeting 5T4, a tumor-associated antigen expressed across various solid tumors, and is currently being evaluated in combination with pembrolizumab.[2] The tissue factor-targeting ADC XB371 is also in phase 1 development, with potential applications in cancers with high TF expression like lung and cervical cancer.[14]
A third program, XB773, is expected to enter phase 1 trials in 2026.[14] As a first-in-class ADC targeting both TROP2 and NECTIN4, XB773 represents a dual-target approach that could potentially overcome resistance mechanisms seen with single-target ADCs like Trodelvy or Padcev.[2, 14] This expansion into the ADC space is critical for long-term revenue diversification, as it positions the company to participate in one of the fastest-growing segments of the oncology market.[2, 3]
Earlier-stage efforts also include XL309, a potent inhibitor of USP1 currently in phase 1 for solid tumors.[2] USP1 plays a key role in the DNA damage response (DDR) pathway, and its inhibition may sensitize tumor cells to other therapies, including PARP inhibitors.[2] In the immunotherapy space, XB628—a bispecific antibody targeting both PD-L1 and NKG2A—is being explored for its potential to enhance anti-tumor immune responses by simultaneously releasing the "brakes" on T cells and natural killer (NK) cells.[2]
The pipeline expansion is also supported by the anticipated clinical entry of XL557, an oral Somatostatin Receptor 2 (SSTR2) agonist, which management believes could offer a complementary treatment modality for patients with neuroendocrine tumors.[14, 19] This breadth of innovation indicates that Exelixis is successfully reinvesting its cabozantinib-generated cash flow into high-potential, clinically differentiated assets.[20, 22]
A significant concern for investors has historically been the potential for generic erosion of the cabozantinib franchise. The core compound patent (the '473 patent) is slated to expire in August 2026.[25, 26] However, recent legal victories have fundamentally shifted the risk profile, extending the company’s period of market exclusivity significantly further into the decade.
In October 2024, Judge Richard Andrews of the U.S. District Court for the District of Delaware issued a pivotal trial opinion in the case of Exelixis, Inc. v. MSN Laboratories.[27] The court found that MSN’s proposed generic product did not infringe the '349 polymorph patent, but critically, it upheld the validity of the "Malate Salt Patents" ('439, '440, and '015).[25, 27, 28] These malate salt patents are set to expire in January 2030.[25, 28]
| Patent Group | Key Patents | Expiration | Legal Status |
|---|---|---|---|
| Core Compound | '473 Patent | August 2026 | Protection ends 2026.[25] |
| Malate Salt | '439, '440, '015 | January 2030 | Upheld in Court (Oct 2024).[25, 27] |
| Polymorph | '349 Patent | October 2030 | Valid but Not Infringed by MSN.[26, 27] |
This victory was viewed by analysts as a "removal of all uncertainties" regarding U.S. market exclusivity.[25] By defending these secondary patents, Exelixis has extended its effective monopoly by nearly four years, a feat that adds billions of dollars to the molecule’s projected long-term cash flows.[25] This extension is vital because it provides the necessary time for zanzalintinib to gain regulatory approval and establish a commercial foothold before the flagship drug faces full generic competition.[22, 25]
The strategic defense of the IP portfolio also saw the dismissal of the patent dispute against Cipla in mid-2024.[29] The case was dismissed without prejudice after only 61 days, which reflects the company’s aggressive and effective strategy in managing Hatch-Waxman litigation.[29] These outcomes collectively suggest that Exelixis has built a formidable "patent fortress" that secures its revenue base through the transition to its second commercial franchise.[3, 25]
As the company matures, its governance and capital allocation strategies have become central to the investment thesis. The April 2026 proxy statement and subsequent filings reveal a board focused on aligning executive incentives with long-term shareholder returns and an aggressive strategy for returning excess capital to investors.[11]
The 2026 proxy highlights a "pay-for-performance" philosophy. CEO Michael Morrissey’s 2025 compensation surged to $33.2 million, a 62% increase over the previous year, driven largely by performance-based equity awards.[30] Specifically, the 2023 PSU performance awards achieved a maximum 175% payout because the company’s relative total shareholder return (TSR) reached the 84th percentile among the Nasdaq Biotechnology Index.[11]
Furthermore, the 2025 special equity awards granted to employees and executives include a rigorous absolute stock price hurdle. For these awards to vest, the company’s common stock must maintain a volume-weighted average price (VWAP) of $60 or higher for a consecutive 90-day period.[11] This $60 hurdle—representing significant upside from the current trading range of $44-$45—underscores management's confidence in the impending value inflection from the zanzalintinib and pipeline milestones.[11, 30, 31]
Exelixis has used its robust cash flow to execute one of the most significant share repurchase programs in the biotech sector. Since authorized in March 2023, the company has returned $2.16 billion to stockholders through stock buybacks.[17, 19, 20]
| Share Repurchase Program | Authorized Amount | Period | Status |
|---|---|---|---|
| Cumulative Since 2023 | $2.16B (Spent) | 2023 - 2025 | 76.7M shares at $28.14 average.[17] |
| Active 2026 Program | $750 Million | Through Dec 2026 | Ongoing execution.[13, 17, 20] |
This aggressive capital return strategy, which includes a remaining $750 million authorized for 2026, serves as a defensive mechanism to support the stock price while reflecting the board’s commitment to balancing R&D investment with direct shareholder returns.[11, 17]
The long-term growth potential of Exelixis is tethered to the expanding global market for kidney cancer and neuroendocrine tumor treatments. Analysis of the global advanced RCC treatment market suggests an increase in value from $8.73 billion in 2025 to $12.52 billion by 2030, reflecting a compound annual growth rate (CAGR) of 7.4%.[32]
| Indication Market | 2025/2026 Value | 2030 Forecast Value | Key Growth Drivers |
|---|---|---|---|
| Advanced RCC | $9.4 Billion (2026) | $12.52 Billion | Rising prevalence; clinical research expansion.[32] |
| Kidney Cancer Drugs | $6.65 Billion (2024) | $9.90 Billion | Targeted therapy and immunotherapy success.[33] |
| Neuroendocrine Tumors | $3.57 Billion (2023) | $6.94 Billion | Increasing incidence; geriatric population growth.[34] |
| NET Treatment | $2.88 Billion (2025) | $4.89 Billion | Growing awareness; orphan drug incentives.[35] |
In the RCC segment, the transition toward targeted therapies and monoclonal antibodies—which accounted for over 85% of kidney cancer market revenue in 2023—plays directly into the company’s strengths with both cabozantinib and zanzalintinib.[33] Similarly, the NET treatment market is expected to reach $3.73 billion to $6.33 billion by 2030, driven by heavy investment in clinical trials by major players like Novartis, Pfizer, and Exelixis.[36, 37, 38]
As of May 2026, Exelixis trades at a valuation that many analysts consider "undervalued" despite its defensive biotech profile and low beta of 0.42.[30] With a market capitalization of approximately $11.4 billion and a healthy P/E ratio of 15.59, the stock is viewed as a "Buy" or "Strong Buy" by a majority of covering firms.[2, 31, 39]
Consensus 12-month price targets hover around $47.00 to $48.48, representing a potential upside of approximately 6% to 15% from the early May trading levels.[39, 40, 41] The high target of $60 align with the executive compensation performance hurdles, suggesting that a significant rerating of the stock is possible if zanzalintinib secures its first major approval in colorectal cancer and reports positive topline data from its other pivotal trials.[11, 22, 39]
The analysis of Exelixis Inc. through the first quarter of 2026 reveals an organization that has successfully de-risked its immediate future. The combination of a record-breaking fiscal year 2025, an earnings-beat-led start to 2026, and the pivotal resolution of patent litigation has created a clear "long-tail" runway for the cabozantinib franchise. The company has moved beyond being a "one-drug story," leveraging its nearly $2.5 billion revenue base to construct a multi-asset oncology engine.
The strategic focus for the remainder of 2026 remains centered on three transformative milestones: the mid-year clinical readouts for nccRCC and CRC OS data, the potential launch of zanzalintinib, and the continued commercial penetration of the $1 billion NET market opportunity. By maintaining disciplined capital allocation and reinvesting profits into high-value modalities like ADCs and bispecific antibodies, Exelixis is not merely preparing for the eventual genericization of its flagship drug; it is actively working to redefine the standard of care in solid tumor oncology. For professional peers and investors, the company represents a rare combination of defensive stability and significant pipeline-driven growth potential, poised to realize a multi-franchise leadership position by the end of the decade.
View Exelixis, Inc. (EXEL) stock page
Loading the interactive version of this report…